Litigation Details for Silvergate Pharmaceuticals Inc. v. Bionpharma Inc. (D. Del. 2016)
✉ Email this page to a colleague
Silvergate Pharmaceuticals Inc. v. Bionpharma Inc. (D. Del. 2016)
| Docket | ⤷ Sign Up | Date Filed | 2016-09-28 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Mitchell S. Goldberg |
| Jury Demand | None | Referred To | |
| Patents | 8,568,747; 8,778,366 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Silvergate Pharmaceuticals Inc. v. Bionpharma Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Silvergate Pharmaceuticals Inc. v. Bionpharma Inc. (D. Del. 2016)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2018-04-03 | 198 | U.S. Patent No. 8,568,747 (“the ’747 Patent”) and U.S. Patent No. 8,778,366 (“the ’366 Patent”), has…include a third patent. While this patent will be litigated with the ’747 and the ’366 Patents, because claim…address only Column 19 of the ’747 Patent, the ’747 Patent and ’366 Patent share a common specification. I…of seven terms contained in the ’747 Patent and the ’366 Patent’s claims.2 1 On May 18, 2017, Chief… before the expiration of the ’747 Patent. The ’366 Patent was issued to the same inventors on | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
